Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 08, 2019

SELL
$62.53 - $70.05 $8.91 Million - $9.98 Million
-142,465 Closed
0 $0
Q4 2018

Feb 05, 2019

SELL
$60.54 - $79.0 $2.81 Million - $3.67 Million
-46,433 Reduced 24.58%
142,465 $8.91 Million
Q3 2018

Nov 09, 2018

BUY
$71.28 - $78.92 $1.36 Million - $1.51 Million
19,139 Added 11.27%
188,898 $14.6 Million
Q2 2018

Aug 08, 2018

BUY
$64.88 - $75.68 $861,087 - $1 Million
13,272 Added 8.48%
169,759 $12 Million
Q1 2018

May 02, 2018

SELL
$72.84 - $88.8 $3.99 Million - $4.87 Million
-54,808 Reduced 25.94%
156,487 $11.8 Million
Q4 2017

Feb 09, 2018

SELL
$71.15 - $83.52 $41.7 Million - $49 Million
-586,192 Reduced 73.5%
211,295 $15.1 Million
Q3 2017

Nov 08, 2017

BUY
$72.11 - $85.47 $57.5 Million - $68.2 Million
797,487
797,487 $64.6 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $116B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Contrarius Investment Management LTD Portfolio

Follow Contrarius Investment Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Contrarius Investment Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Contrarius Investment Management LTD with notifications on news.